Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients
Status:
Unknown status
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The study is designed as a Phase II, prospective, non randomized, open-label, single arm,
multicenter trial, in which patients with locally advanced or metastatic ACC not amenable to
complete surgical resection and progressing to cytotoxic chemotherapy will receive Sorafenib
plus metronomic chemotherapy as treatment.The aim of this phase II trial is to evaluate the
clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in
patients with locally advanced or metastatic ACC who progressed after first or second line
chemotherapy.